Primary Recipient

REGENERX BIOPHARMACEUTICALS, INC.

Amount

$3,000,000.00

Award Date

5/13/2010

Administering Agency

Health and Human Services, Department of / National Institutes of Health

CDFA Number

93.701

CDFA Program Title

Trans-NIH Recovery Act Research Support

Description

RegeneRx Biopharmaceuticals Inc. has the long-term goal of developing Thymosin Beta 4 (TB4), a naturally occurring peptide, for use in the treatment of ST-elevation myocardial infarction (STEMI). There are no pharmacological agents on the market to preven